POINT Biopharma Global Inc.
PNT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PNT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2023.
Tracking 8 pipeline candidates · 28 clinical trials for POINT Biopharma Global Inc..
Run POINT Biopharma Global Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available POINT Biopharma Global Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
34.9 months
OCF -$28M · Net income -$25M
Lead: Phase 3
8 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is POINT Biopharma Global Inc.'s lead drug candidate?
POINT Biopharma Global Inc.'s most advanced tracked candidate is 177lu-pnt2002 (Phase 3) for metastatic castration-resistant prostate cancer (mCRPC).
Who is the CEO of POINT Biopharma Global Inc.?
Joe Mc is the chief executive officer of POINT Biopharma Global Inc. (PNT).
What therapeutic areas does POINT Biopharma Global Inc. focus on?
POINT Biopharma Global Inc. develops therapies across Oncology, Neurology, Immunology, Ophthalmology, Infectious Disease, Dermatology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.